Neurocrine Biosciences | NBIX - Current Assets


Neurocrine Biosciences reported $2.52B in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
AbbVie USD 29.06B 523M Dec/2025
Acadia Pharmaceuticals USD 1.06B 14.31M Dec/2025
Agios Pharmaceuticals USD 942.05M 91.06M Dec/2025
ALKERMES USD 1.93B 187.5M Dec/2025
Alnylam Pharmaceuticals USD 4.05B 97.85M Dec/2025
Amgen USD 29.06B 1.17B Dec/2025
Biogen USD 8.97B 37.5M Dec/2025
BioMarin Pharmaceutical USD 3.95B 98.95M Dec/2025
Cytokinetics USD 916.97M 60.37M Dec/2025
Enanta Pharmaceuticals USD 198.68M 5.65M Dec/2025
Exelixis USD 1.44B 41.03M Dec/2025
Gilead Sciences USD 19.89B 1.05B Dec/2025
Halozyme Therapeutics USD 825.21M 503.54M Dec/2025
Incyte USD 5.02B 746.01M Dec/2025
Ionis Pharmaceuticals USD 2.99B 471.01M Dec/2025
Nektar Therapeutics USD 281.36M 94.79M Sep/2025
Neurocrine Biosciences USD 2.52B 364.3M Dec/2025
Pfizer USD 46.92B 3.22B Sep/2025
Prothena USD 315.19M 24.78M Dec/2025
Regeneron Pharmaceuticals USD 18.02B 41.2M Dec/2025
Repligen USD 1.14B 40.9M Dec/2025
Rigel Pharmaceuticals USD 214.93M 39.53M Sep/2025
Sarepta Therapeutics USD 2.54B 184.37M Dec/2025
Teva Pharmaceutical Industries USD 13.95B 1.21B Dec/2025
Ultragenyx Pharmaceutical USD 643.21M 76.58M Sep/2025
Vertex Pharmaceuticals USD 11.2B 631.4M Dec/2025
Xoma USD 110.71M 5.78M Sep/2025